Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

James Spicer

King’s College London

United Kingdom

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Academic Page

Research Interests

Immunology

70%

Internal Medicine

20%

Immunotherapy

50%

Tumor Suppressor

40%

Cancer Biology

40%

Oncology

30%

Tumor Immunology

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles20

PD-L1 imaging with [99mTc]NM-01 SPECT/CT is associated with metabolic response to pembrolizumab with/without chemotherapy in advanced lung cancer

Article Link

Year:

2025

An oral heme oxygenase inhibitor targets immunosuppressive perivascular macrophages in preclinical models of cancer

Article Link

Year:

2025

Tumor microenvironments with an active type I IFN response are sensitive to inhibitors of heme degradation

Article Link

Year:

2025

Assessment of biophysical properties of the first-in-class anti-cancer IgE antibody drug MOv18 IgE demonstrates monomeric purity and stability

Article Link

Year:

2025

Non-Allergic Urticarial Skin Reactions Associated With MOv18 IgE, a First-In-Class IgE Antibody Recognising Folate Receptor Alpha

Article Link

Year:

2025

Hyperinflammatory repolarisation of ovarian cancer patient macrophages by anti-tumour IgE antibody, MOv18, restricts an immunosuppressive macrophage:Treg cell interaction

Article Link

Year:

2025

A Retrospective Evaluation of PD-L1 Expression and Heterogeneity in Early-Stage Non-Small Cell Lung Cancer (REPLICA)

Article Link

Year:

2025

Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production

Article Link

Year:

2025

Phase Ib Study of the Immunocytokine Simlukafusp Alfa (FAP-IL2v) in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma

Article Link

Year:

2024

Real-World Analysis of Survival and Treatment Efficacy in Stage IIIA-N2 Non-Small Cell Lung Cancer

Article Link

Year:

2024

Intra-Tumoral pan-ErbB Targeted CAR-T for Head and Neck Squamous Cell Carcinoma: Interim Analysis of the T4 Immunotherapy Study

Article Link

Year:

2023

Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha

Article Link

Year:

2023

B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanoma

Article Link

Year:

2023

REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment

Article Link

Year:

2023

Anti-cancer Pro-inflammatory Effects of an IgE Antibody Targeting the Melanoma-associated Antigen Chondroitin Sulfate Proteoglycan 4

Article Link

Year:

2023

Revitalising cancer trials post-pandemic

Article Link

Year:

2023

The threat of triple M and autoimmune overlap syndromes with immune checkpoint inhibitors - A series of case reports

Article Link

Year:

2023

Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World Study

Article Link

Year:

2022

Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes

Article Link

Year:

2022

18F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer

Article Link

Year:

2022

Collaborators28

Fiona Reid

King’s College London

UNITED KINGDOM

Meriem Bahri

King's College London

UNITED KINGDOM

Philip Blower

King’s College London

UNITED KINGDOM

Anna Schurich

King’s College London

UNITED KINGDOM

Panagiotis Karagiannis

University Medical Center Hamburg-Eppendorf

GERMANY

Maria Elstad

King’s College London

UNITED KINGDOM

Richard Beatson

University College London

UNITED KINGDOM

Sophie Papa

King’s College London

UNITED KINGDOM

Alicia Michelle Chenoweth

King’s College London

UNITED KINGDOM

Udai Banerji

NIHR Professor of Molecular Cancer Pharmacology & Honorary Consultant in Medical Oncology

The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust

UNITED KINGDOM

Vicky Goh

King’s College London

UNITED KINGDOM

Franca Fraternali

Professor of Bioinformatics and Computational Biology

King’s College London

UNITED KINGDOM

Mariangela Figini

Fondazione IRCCS Istituto Nazionale dei Tumori

ITALY

Akshay Patel

University of Birmingham

UNITED KINGDOM

Rebecca S. Kristeleit

University of Arizona College of Medicine

UNITED STATES

Hans Prenen

Antwerp University Hospital

BELGIUM

Nick Beckley-Hoelscher

King's College London

UNITED KINGDOM

Debashis Sarker

King’s College London

UNITED KINGDOM

Jit Sarkar

King's College London

UNITED KINGDOM

Manil Subesinghe

King’s College London

UNITED KINGDOM

Chris Corrigan

King’s College London

UNITED KINGDOM

Jitesh Chauhan

King's College London

UNITED KINGDOM

Sophia Karagiannis

King’s College London

UNITED KINGDOM

Deborah Dunn-Walters

University of Surrey

UNITED KINGDOM

John Maher

King’s College London

UNITED KINGDOM

Panagiotis Maghsoudlou

Academic Clinical Lecturer in Ophthalmology

University of Bristol

UNITED KINGDOM

Gary Cook

King’s College London

UNITED KINGDOM

Chara Stavraka

NIHR Clinical Lecturer

King’s College London

UNITED KINGDOM

How do I reach out?

Meet Kite AI